OncoMatch/Clinical Trials/NCT06038461

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Is NCT06038461 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumors.

Phase 1/2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06038461Data as of May 2026

Treatment: Surufatinib Combined With Temozolomide and S-1 — This is a prospective, open, single-center study evaluating the efficacy and safety of surufatinib Combined With Temozolomide and S-1 as the first-line treatment of advanced neuroendocrine tumors

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Biomarker criteria

Required: MGMT 0/1+ (0/1+)

advanced MGMT0/1+ (G1, G2 or G3) neuroendocrine tumor

Disease stage

Grade: g1g2g3

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Adequate hematologic function

Kidney function

Adequate renal function; Urine protein < ++ . If Urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g

Liver function

Adequate hepatic function

Cardiac function

Adequate heart function

Adequate hepatic, renal, heart, and hematologic functions; Urine protein < ++ . If Urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify